{"id":"W4391333747","doi":"10.1200/jco.2024.42.4_suppl.625","title":"Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Tolerability; Cisplatin; Internal medicine; Oncology; Nausea; Chemotherapy; Adverse effect; Carboplatin; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001537323,0.001383984,0.001482845,0.0004572856,0.0004218123,0.001317746,0.001138254,0.001775982,0.004603135],"category_scores_gemma":[0.0009351854,0.0006174474,0.001278071,0.0003845426,0.0007536242,0.001474286,0.0004508286,0.003988117,0.001083436],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001082874,"about_ca_system_score_gemma":0.001472665,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001109143,"about_ca_topic_score_gemma":0.002664271,"domain_scores_codex":[0.9996036,0.0001638766,0.00002248343,0.00006511768,0.00003549782,0.0001093864],"domain_scores_gemma":[0.9993495,0.00009124893,0.0001165931,0.00006358469,0.00003722086,0.0003417773],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7107052,0.1059484,0.005448385,0.001098587,0.002441073,0.0005019989,0.0003779131,0.006765988,0.03556198,0.0006236292,0.006934793,0.1235921],"study_design_scores_gemma":[0.4193582,0.5597802,0.007226526,0.00007118696,0.0005055545,0.0004978694,0.00009302265,0.002161613,0.004956758,0.0004162189,0.004894651,0.00003819747],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860907,0.002712468,0.001001959,0.0007561793,0.0002291103,0.003476884,0.001822251,0.0001553683,0.003755116],"genre_scores_gemma":[0.9881962,0.001649885,0.001558012,0.0009016727,0.0001170401,0.001749938,0.002739668,0.00003440599,0.003053075],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004603135,"threshold_uncertainty_score":0.01539904,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08707493923184538,"score_gpt":0.4415278125938331,"score_spread":0.3544528733619877,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}